HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway (Q42021947)
Jump to navigation
Jump to search
scientific article published on 4 October 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway |
scientific article published on 4 October 2016 |
Statements
1 reference
HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway (English)
1 reference
1 reference
Laura Lucarini
1 reference
Mariaconcetta Durante
1 reference
Giulia Boccalini
1 reference
Laura Calosi
1 reference
Flavio Moroni
1 reference
Emanuela Masini
1 reference
Guido Mannaioni
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference